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Both normal wound healing and tumor angiogenesis are mitigated by the sequential, care-
fully orchestrated release of growth stimulators and inhibitors. These regulators are
released from platelet clots formed at the sites of activated endothelium in a temporally and
spatially controlled manner, and the order of their release depends on their affinity to glycos-
aminoglycans (GAG) such as heparan sulfate (HS) within the extracellular matrix, and plate-
let open canallicular system. The formation of vessel sprouts, triggered by angiogenesis
regulating factors with lowest affinities for heparan sulfate (e.g. VEGF), is followed by ves-
sel-stabilizing PDGF-B or bFGF with medium affinity for HS, and by inhibitors such as PF-4
and TSP-1 with the highest affinities for HS. The invasive wound-like edge of growing
tumors has an overabundance of angiogenesis stimulators, and we propose that their abun-
dance out-competes angiogenesis inhibitors, effectively preventing inhibition of angiogene-
sis and vessel maturation. We evaluate this hypothesis using an experimentally motivated
agent-based model, and propose a general theoretical framework for understanding mecha-
nistic similarities and differences between the processes of normal wound healing and path-
ological angiogenesis from the point of view of competitive inhibition.
Introduction
A state of chronic inflammation and active angiogenesis, characteristic of many tumors, has
led to tumors often being considered “wounds that never heal” [1]. The inflammation accom-
panying angiogenesis and the associated blood vessel formation, do not necessarily follow tis-
sue planes, but are effective in supplying oxygen, nutrients and in promoting further growth.
To understand and potentially modulate tumor angiogenesis, we need to find ways in which
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tumor angiogenesis differs from normal wound healing. More specifically, we need to identify
the mechanisms that lead to normal pruning, stabilization and inhibition of vascular sprouting
in wound healing, and why these may be absent in tumor angiogenesis. Both the physiological
and pathological variants of angiogenesis are regulated by carefully orchestrated, temporally
and spatially controlled signals from surrounding tissues, and it is the sum of these signals the
leads to sequential release of stimulators and inhibitors of angiogenesis. We have shown previ-
ously that angiogenesis regulators are actively, and against a concentration gradient seques-
tered in platelets [2], and that stimulators and inhibitors of angiogenesis are differentially
released [3, 4].
Platelets are formed by megakaryocytes in the bone marrow, and released into the circula-
tion via pseudopodial extensions [5]. Due to their very short half-life, platelets are continuously
renewed and their angiogenesis cargo updated depending on demand. Because for every μL of
blood, there are 150,000–450,000 platelets, a typical adult with an average of 5 liters of cardiac
output would have 0.750–2.250 trillion circulating platelets at any given time. This fast turn-
over of large number of circulating platelets containing high concentrations of angiogenesis
regulators facilitates a very responsive system for regulating localized angiogenesis at sites of
activated endothelium, where platelets form a growth factor rich clots as part of the extracellu-
lar matrix (ECM). Platelets, in addition to regulating amounts of angiogenesis regulators at the
level of megakaryocyte synthesis [4], use their heavily GAG coated membrane of the open
canallicular system, to pick up additional angiogenesis regulators from the tumor microenvi-
ronment [2, 6, 7]. During platelet activation, specific surface receptors induce a shape change,
extension of lamellipodia and filopodia, and subsequent attachment. The most common plate-
let aggregation agonists used in clinical laboratories are epinephrine, adenosine di-phosphate
(ADP), and thrombin, but in vivo, the process is more frequently regulated by fibrin(ogen),
(pro)thrombin, von Willebrand factor (VWF) and cleaved products of collagen. Under physio-
logical conditions, platelets are recruited to the wound, and the clot formed at the site effec-
tively traps the enclosed angiogenesis regulators within the ECM matrix, liberating these ECM
bound or “trapped” angiogenesis regulators through the action of enzymes such as thrombin
[8], heparinase [9], or other locally secreted proteases such as plasminogen activator or
collagen.
One of the best described mechanisms of differential release of growth factor from platelets
is the proteinase-activated system, presented in 2005 by Li Ma and David Wallace [10]. They
showed that the release of growth factors from platelets during the healing of gastrointestinal
ulcers was mediated by stimulation of specific proteinase-activated receptors (PARs). The
release of pro-angiogenesis proteins, such as vascular endothelial growth factor (VEGF) was
triggered by the high affinity thrombin receptor (PAR-1) preferentially activated in low throm-
bin state, whereas release of angiogenesis inhibitors such as endostatin was triggered by PAR-
4, the low affinity receptor triggered in thrombin-rich environment. The gradual transition
from low to high concentrations of thrombin is an example of the intricate, highly orches-
trated, sequential release of cytokines as the concentrations of proteases in the wound micro-
environment change.
The second, less well documented system for orchestrating the sequential release of angio-
genesis regulators from platelet-rich ECM at the site of vascular injury is the highly complex
system of tissue specific anchors such as heparan sulfate. Throughout this manuscript the term
heparin and heparan sulfate are used with the understanding that heparin refers to all heparin
moieties in general, i.e. circulating as well as tissue bound, whereas heparan sulfate refers only
to tissue bound heparin moiety. Angiogenesis regulators, at least those described to date, have
heparin-binding domains and the isoforms often vary in their heparin-binding domain only.
This may be a developmentally important evolutionary adaptation determining the tissue
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specific isoforms. For example, VEGF121, a weakly acidic, soluble protein fails to bind heparin
and circulates as a decoy, VEGF165, the predominant species, is also diffusible, but remains
bound to ECM in lung and kidney tissues, VEGF189 and VEGF206, the more basic proteins
binding heparin with greater affinity are sequestered in the extracellular matrix, and VEGF206
binds very tightly and has only been identified in human and murine fetal liver cDNA librar-
ies. We suggest that the degree to which angiogenesis regulators bind to GAGs is important in
determining the sequence of their release and action.
As we have previously documented using open-ended, mass spectrometry-facilitated com-
parison of proteomes of platelet from healthy non-tumor-bearing mice and their tumor-bear-
ing counterparts, the presence of a tumor leads to active sequestration angiogenesis regulators
in platelets. Upon sequencing the proteins differentially expressed in platelets of tumor bearing
mice [2, 6] and humans [11] we found that the most common denominator facilitating the
sequestration of proteins in platelets was the ability to bind heparin, suggesting that this was
the mechanism of sequestration. Thus, in the setting of a wound the sequence would be as fol-
lows: i) VEGF stimulates the initiation of an early vascular sprout (tip cell) [12], ii) the sprout
growth and lumenization (stalk cells) are facilitated by bFGF [13, 14]. iii) the proliferation and
stabilization of endothelial cells and tube formation is facilitated by medium affinity heparan
sulfate binding proteins such as bFGF and platelet derived growth factor (PDGF-B), and finally
iv) inhibition of angiogenesis is facilitated by angiogenesis inhibitors such as platelet factor-4
(PF-4) and thrombospondin (TSP-1), which have the highest affinity for HS. The inhibitors of
angiogenesis are released last during wound healing and continue to be released under normal
physiological conditions. Most of the regeneration and re-establishment of normal tissue
architecture during healing occurs by vessel pruning and is accomplished by endogenous
inhibitors such as endostatin, tumstatin, thrombospondin-1 and angiostatin, all of which are
cleaved products of the collagen matrix [15].
The above-described well-orchestrated system of release of angiogenesis regulators from
the platelet-rich ECM is based on cell-cell interactions. Specific signals produced during
wound healing by cell-cell interactions initiate, promote or terminate formation of new blood
vessels. However, in order to do so, angiogenesis regulators need to be bound to tissue glycos-
aminoglycans (GAGs) such as heparan sulfate (HS) on the cells’ surface [16–18]. This struc-
tural anchoring to the tissue facilitates receptor signaling [19] and enables cell-cell feedback
triggering or inhibiting secretion of enzymes such as heparinase from fibroblasts and other
stromal elements. In contrast, increased heparinase secretion degrades HS, effectively destroy-
ing the tissue anchors and increasing the turnover of angiogenesis regulators. For as long as
tissue injury exists, the up-regulation of GAG formation and angiogenesis continue, but with
healing, as increasing amounts of thrombin and scar tissue are deposited, HS is down-regu-
lated and the system turns off. It should be stressed here that the ‘normal physiological state’ of
post-natal angiogenesis is ‘off’ except for placental implantation and wound healing. The
absence of postnatal angiogenesis is further supported by the finding that the concentration of
angiogenesis inhibitors such as TSP-1 and PF-4 in platelets is orders of magnitudes higher
than that of stimulators [11], and by the predominance of angiogenesis inhibitors in tissues
because most of the HS sites are firmly occupied by high-affinity angiogenesis inhibitors such
as TSP-1 and PF-4.
This quiescence is altered in a cancer setting. The oncogene activation of tumor stroma
leads to inflammation, activation of proliferative pathways and the constantly advancing
tumor edge does not permit accumulation of thrombin, down-regulation of HS, and binding
of angiogenesis inhibitors. Because stronger bonds are needed for high affinity binding, it
requires more time and more stable environment than that provided by an advancing edge.
This manuscript presents biological experiments evaluating the manner in which heparin
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affinity of angiogenesis regulators affects the order of growth factor elution from platelets, and
offers a conceptual framework, which uses an agent-based model to simulate the data in silico.
The proposed theoretical framework suggests that wound healing is governed by a competitive
interaction of high and low affinity angiogenesis regulators for tissue binding sites.
Materials and Methods
In vitro experiments
We have previously documented the presence of angiogenesis regulators in normal healthy
platelets [11], and in platelets of tumor bearing animals [2, 6]. To demonstrate the sequential
release of angiogenesis stimulators and inhibitors from a thrombus, we used NaCl elution of
proteins from a column of activated human platelets (a clot). Platelets were collected from
healthy human volunteers using direct venipuncture into standard sodium citrate (1/9 v/v)
vacutainer tubes. Individuals with history of cancer, inflammatory disease, diabetes or non-
steroidal anti-inflammatory drug use were excluded from the study. The protocol for platelet
collection (IRB# 11096) was specifically approved by the Tufts Medical Center Institutional
Ethics Review Board), and signed written consent was obtained for each of the healthy volun-
teers used for this study.
We used salt elution as a surrogate for tissue proteases because the relationship between
increasing concentration of salt and growth factor affinity is linear, and independent of other
environmental conditions such as temperature or acidity. This is a standard elusion method
used in the majority of studies investigating heparin-binding growth factors [20–22]. A platelet
clot was made from 1mL of platelet rich plasma, and incubated with heparin affinity beads in a
heparin sepharose column (GE healthcare). The platelet clot and heparin column was allowed
to equilibrate for 3 hours at 37˚C. The column was then washed using with 10 mL of physio-
logical saline [0.154M NaCl] (i.e 10 volumes of the original volume of beads in the column,
which is 1 mL). The proteins were eluted with 1 mL NaCl of increasing molar concentrations
between 0.154 and 4M. In this experiment, the NaCl acts by disrupting the ionic interactions
between heparan sulfate and the corresponding growth factor. Under physiological conditions,
heparinase would cleave the heparan sulfate chain to which the growth factor is bound.
Each 1mL elution was then quantified using an ELISA assay (R and D Systems Inc) for each
corresponding protein, VEGF, PF-4, TSP-1 and PDGF-BB. The observed plateau in PF-4 was
due to the detection limit of the PF-4 ELISA. The experiments were repeated three times with
technical duplicates for each faction. Negative values due to noise or as a consequence of
approximations done using linear regression were corrected to 0. Platelets contain angiogene-
sis inhibitors in quantities that are many fold higher than those of angiogenesis stimulators. In
order to accommodate these widely discrepant amounts on a single graph, we had to divide
the values for PF-4 by 50, the values of TSP-1 by 100, and the values of PDGF-B by 10. The
results are reported in Fig 1.
To confirm the relevance of the experiment to physiological conditions we repeated the
experiment using a limited dose response curve of heparinase (see S1 Fig). Even though the
action of heparinase is much more dependent on temperature, acidity, oxygen availability, as
well as on other tissue-dependent factors, the results were qualitatively consistent with results
obtained using NaCl.
Agent-based model
The overreaching goal of the endeavor was to understand the role of platelets associated angio-
genesis regulators in normal physiological angiogenesis and its pathological counterpart. We
explored the processes from the premise that because platelet angiogenesis regulators remain
Normal Wound Healing and Tumor Angiogenesis as a Game of Competitive Inhibition
PLOS ONE | DOI:10.1371/journal.pone.0166655 December 9, 2016 4 / 16
associated with the clot, they get incorporated in the ECM, and their effect is regulated by com-
petition for HS binding sites. In this framework, should the stimulators out-compete the inhib-
itors, one would expect to see unrestrained angiogenesis.
To evaluate the hypothesis, we constructed an agent-based in Netlogo 5.0.2, a freely avail-
able agent-based modeling platform, where a 2-dimensional 51x51 lattice represents space.
Each grid on the lattice represents a discrete microenvironment, the properties of which are
given below. The model allows for 2601 microenvironments. Cells occupy coordinates in con-
tinuous space; more than one cell can occupy a single microenvironment. Time is modeled in
discrete steps. We focus on three broad classes of growth factors in this model, and the classes
are characterized by their affinities for HS. More specifically, we refer to stimulators of angio-
genesis (VEGF) as low-affinity growth factors (LA), to vessel stabilizers (PDGF-B) as medium
affinity growth factors (MA), and to inhibitors (PF-4, TSP-1) as high-affinity growth factors
(HA).
The specific assumptions used for this model for each agent and for the microenvironments
are as follows:
Properties of cells. cells of the stroma are populated on the grid randomly. Cells are non-
motile and are characterized by a parameter that determines the number of binding sites to
which the growth factors can attach. The number of binding sites is taken from a random dis-
tribution, with a predefined mean and variance. The number of the free binding sites is
decreased as they become occupied by a growth factor, and increased, when the growth factor
is cleaved by heparinase.
Properties of low affinity (LA) growth factors. Low affinity (LA, VEGF) cytokines are
the first type of growth factors to be released into the microenvironment at the beginning of
the simulation. LA are motile and move randomly throughout the grid. LA are characterized
Fig 1. Release of angiogenesis regulators from platelets is sequential. The activity of tissue proteases such as heparinase, which is an
enzyme that cleaves heparan sulfate from the cell membranes, is simulated by increased concentrations of NaCl. As shown in a, b and c,
higher concentrations of NaCl are required for the release of growth factors with higher heparan sulfate affinities, going from VEGF (a) to
PDGF-B (b) to PF-4 and TSP-1 (c). The observed plateau in PF-4 was due to the detection limit of the PF-4 ELISA. The predicted shape of
the curve in the absence of ELISA detection limit is shown as a dotted red line. Fig 1D shows an overlay of each protein with PDGF-B divided
by 10, PF-4 divided by 50 and TSP-1 divided by 100. Each experiment was repeated 3 times in technical duplicate.
doi:10.1371/journal.pone.0166655.g001
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by 2 parameters: probability of attachment to a free binding site, and sensitivity to heparinase;
LA become cleaved and release the binding sites at the lowest concentration of heparinase
compared to other growth factors. Once they encounter a cell, they evaluate the availability of
free binding sites. If a binding site is available, they attach with a certain pre-defined probabil-
ity, and become cleaved depending on the concentration of heparinase in the corresponding
microenvironment. When they attach, the decrease the number of binding sites available to
other growth factors. Number of free binding sites is restored when Las are cleaved.
Properties of medium affinity (MA) growth factors. Medium affinity (MA, PDGF) cyto-
kines are the second type of growth factors to be released into the microenvironment at the
beginning of the simulation. MAs are motile and move randomly throughout the grid. MAs
are also characterized by 2 parameters: probability of attachment to a free binding site, and
sensitivity to heparinase; MAs become cleaved and release the binding sites at the higher con-
centration of heparinase compared to LAs but lower than HAs. Once MAs encounter a cell,
and free binding sites are available, they attach with a certain pre-defined probability, and
become cleaved depending on the concentration of heparinase in the corresponding microen-
vironment. When they attach, the number of binding sites available to other growth factors is
reduced. The number of free binding sites is restored after MAs are cleaved.
Properties of high affinity (HA) growth factors. High affinity (MA, PF-4 and TSP-1)
cytokines are the third and last type of growth factors to be released into the microenviron-
ment at the beginning of the simulation. Like LA and MA, HA are motile and move randomly
throughout the grid. HA are also characterized by 2 parameters: probability of attachment to a
free binding site, and sensitivity to heparinase; HA become cleaved and release the binding
sites at highest concentration of heparinase compared to other growth factors: once they
become attached, they take a long time to become cleaved. Once HA encounter a cell, they
evaluate the availability of free binding sites. If a binding site is available, they attach with a cer-
tain pre-defined probability, and become cleaved depending on the concentration of hepari-
nase in the corresponding microenvironment. When they attach, the decrease the number of
binding sites available to other growth factors. Number of free binding sites is restored after
HA become cleaved.
Properties of the microenvironments. Each microenvironment is characterized by some
amount of heparinase, different for each patch. Heparinase is removed and replenished in the
microenvironments continuously over time to simulate heparinase flux in the tissue microen-
vironment. The concentration of heparinase is visually depicted in the simulation in yellow;
higher levels of heparinase in the microenvironment are represented by darker shades of yel-
low (see Fig 2). The NetLogo program code is attached in Supporting Information (see S1
Code). A homeostatic balance of heparinase is maintained over time throughout the grid.
The model is initialized after the growth factors have been sequentially released from plate-
lets (not included in this model), starting from LA, followed by MA, and finally by HA. At
each time step, the following sequence of events is realized:
1. Cytokines are released into the tumor microenvironment (once in the beginning for simu-
lation of normal wound healing; at each time step in case of simulation of a tumor)
2. Cytokines move randomly throughout the grid. Once they encounter a cell, they evaluate
availability of binding sites.
3. If a binding site is available, the growth factor attaches, thereby reducing the number of
available binding sites.
4. Depending in the type of cytokine and on the amount of heparinase in the corresponding
microenvironment, the cytokine remains bound or becomes cleaved. LA become cleaved at
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lowest concentration of heparinase, followed by MA, and finally followed by HA, which
become cleaved only at highest levels of heparinase.
5. Heparinase is randomly removed or replenished from each microenvironment.
6. In the presence of a tumor, LA, MA and/or HA may become replenished as well, depending
on each simulated case. Addition of LA and MA creates competition for binding sites for
HA.
In this model we do not incorporate formation of blood vessels as a result of such signaling
as it is outside the scope of this particular investigation. This model is proof-of-concept, aimed
to evaluate the hypothesis that presence of competition for binding sites may cause continuous
presence of growth factors that are capable of constant pro-angiogenesis signaling.
Parameter estimation
In the experiment described above, we demonstrated that different concentrations of NaCl,
which served as a proxy for heparinase, cleave distinct angiogenesis regulatory proteins from
the column. Angiogenesis stimulators (VEGF) have the lowest affinity for NaCl and thus
heparinase, followed by blood vessel stabilizers (PDGF), which have medium affinity for NaCl,
followed by angiogenesis inhibitors (PF-4 and TSP-1), which have the highest affinity for
heparinase. Since NaCl is a proxy for heparinase, we are not able to retrieve exact parameter
values for affinities of angiogenesis regulators for heparinase; however, we can use the
Fig 2. A snapshot of the proposed agent-based model. (A) Model initialization. The grid is populated by cells, which are characterized by
pre-determined number of binding sites. The color changes in the microenvironments represent heparinase concentration. Darker patches
correspond to higher concentrations of heparinase; lighter patches correspond to lower levels of heparinase. (B) After the simulation has
begun, the growth factors LA, MA and HA mode randomly throughout the grid. Once they encounter a cell with free binding sites (red
crosses), they occupy them, and thereby decreasing the number of available sites (numbers by the cell agents decreases, reflecting the
number of available sites). Growth factors become cleaved depending on the current concentration of heparinase in the corresponding
microenvironment. The NetLogo code for this model is attached in Supporting Information.
doi:10.1371/journal.pone.0166655.g002
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extrapolated relationships and relative values of parameters for the purposes of our proof-of-
concept model. Specifically, the rate of detachment of angiogenesis stimulators (VEGF) from
binding sites will be lower compared to rates of detachment of blood vessel stabilizers (PDGF),
which in turn will be lower than that of angiogenesis inhibitors (PF-4 and TSP-1).
Results
We have shown in earlier studies that the majority of platelet associated angiogenesis regulat-
ing proteins are retained in the clot upon platelet aggregation and activation [2]. This earlier
work [2] challenged the widely accepted assumption that platelets degranulate and thus release
proteins en masse. We now hypothesize that this is a direct consequence of the varying heparin
sulfate-binding affinities of stimulators and inhibitors of angiogenesis, and that there is a spe-
cific order to the release of angiogenesis regulators from the platelet clots. Using increasing
concentration of NaCl as a surrogate for increasing concentration of tissue proteases, our
results indicate that platelet-associated angiogenesis regulators may be eluted in sequence cor-
responding to their heparin-binding affinities. A similar sequential release has been previously
reported for tissues but not in the context of platelets [20]. More specifically, VEGF, a low-
affinity angiogenesis stimulator that induces sprout formation, is released first (Fig 1a), fol-
lowed by medium-affinity growth factors, such as PDGF-B (Fig 1b), and subsequently by high-
est-affinity inhibitors, such as PF-4 (Fig 1c). That is, as the concentrations of stimulators peak,
the concentration of inhibitors predominates and angiogenesis returns to the physiologically
dominant state, i.e. quiescence of angiogenesis (Fig 1d). The need for tissue- VEGF concentra-
tion gradients may be the main reason that higher organisms have tissue-dependent expres-
sion of specific VEGF isoforms, each of which differs not in the main protein core, but in their
ability to bind heparin. We can appreciate two peaks of VEGF in Fig 1 (one at 0.154 M NaCl,
and another one at 1M NaCl), most likely due to VEGF165 and VEGF189 isoforms. Unfortu-
nately, because present ELISA assays cannot distinguish between VEGF165, VEGF189 and
VEGF206 an experimental confirmation is not possible. In contrast, the two peaks of PF-4 in
Fig 1c are more likely caused by the abundance of PF-4 in platelets, and a wash out of its excess
at low NaCl concentrations, as no isoforms of PF-4 have been described.
Simulation of normal wound healing
Our first goal was to replicate using an agent-based modeling method, the experimentally
observed pattern of sequential release of cytokines, observed in Fig 1. The starting values for
low-affinity (LA), medium-affinity (MA) and high-affinity (HA) used for the simulation were
taken from [11]. Because experimentally reported physiological concentrations of angiogenesis
inhibitors (HA) are several orders of magnitude higher, we have adjusted these values for the
simulation. This computational adjustment does not, from model construction point of view,
qualitatively affect the predicted dynamics. The only predicted change in the outcome is the
time of the simulation, because more HA growth factors would bind and release over time. We
ran 10 simulations for the initial parameter set, and data was collected by counting the number
of each type of bound cytokines at each time point. The number of each cytokine was averaged
and the summary given in Fig 3. All of the data for individual curves for all ten simulations can
be found in supplementary materials (see S2–S8 Figs for individual simulations). As one can
see in Fig 3, the model reproduces a pattern consistent with expected behavior of angiogenesis
regulators during normal wound healing. Importantly, this pattern was reproduced using a set
of few basic assumptions about growth factors with different affinities competing for available
binding sites.
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Cytokine competition during tumor angiogenesis
A number of studies report increased secretion of lower and medium affinity growth factors
(e.g. VEGF and PDGF-B) in the tumor microenvironment [20]. It is also well documented
that expression of glycosaminoglycans such as heparan sulfate is increased at the sites active
injury [23] or tumor [16]. Within a competition-based framework proposed here, we hypothe-
size that increased inflow and turnover of lower-affinity growth factors leads to higher-affinity
growth factors (inhibitors) being outcompeted for binding sites leading to inability of inhibi-
tors to bind and restrain angiogenesis. The HS-tightly binding angiogenesis inhibitors such as
PF4 and TSP1 may also not be released from the platelet clot as they require more time and
protease activity to be released. Thus, while the process of new tumor vessel formation would
commence in the same way as vessel formation in wound healing process, it would not
Fig 3. Simulation of cytokine release during normal wound healing. Angiogenesis regulators bound to a heparin
sulfate moiety in platelet clots are eluted using incremental concentrations of sodium chloride as a surrogate for tissue
proteases. The experimentally observed release of growth factors appears to suggest that angiogenesis regulators are
released in order of their affinity for heparan sulfate, with VEGF having the lowest affinity, and PF-4 and TSP-1 the highest.
doi:10.1371/journal.pone.0166655.g003
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terminate by release of inhibitors. The model is supported by the observation that the levels of
PF-4, a tumor angiogenesis inhibitor are decreased with tumor progression [6].
In order to evaluate this hypothesis, we modify the model to allow for a continuous inflow
of low and medium affinity growth factors from the tumor cells, or from stromal elements in
response to hypoxia. We run five different sets of numerical experiments and compare the pre-
dicted curves to the ones that correspond to the process of normal wound healing, given in Fig
3. More specifically, we introduce the following modifications: a) 1 additional LA per run, b) 1
additional LA and 1 MA, c) 2LA 1MA, d) 5LA, 1MA e) 5LA 1MA 1HA. The values were cho-
sen arbitrarily, for the purposes of evaluation of the predicted effects of different relative rates
of inflow of growth factors of various types. The results of the simulations can be seen in Fig 4,
and details of the simulations are available in supplementary materials (see S3–S8 Figs for indi-
vidual simulations).
As can be seen in these examples, a continuous release of lower and medium affinity cyto-
kines leads to inhibitors being out-competed from binding sites and unable to restrain angio-
genesis. The relative rates of inflow can be varied along with variations of growth factors based
on tumor or tissue specificity. A specific sub-study may be modeling tumor dynamics empha-
sizing differences between actively growing and dormant tumors.
Discussion
A number of mathematical models have previously been proposed to describe pathological
angiogenesis, using both equation-based and agent-based models (see, for instance [24–29]).
Fig 4. Summary of simulations for normal and pathological angiogenesis. The simulation of cytokine profiles in normal wound healing
(A) is distinctly different from the cytokine profiles during tumor angiogenesis (B-F). In order to simulate tumor angiogenesis, a number of
scenarios were explored: The release of 1 additional low affinity cytokine released into the model microenvironment per run (B); 1 additional
low affinity (LA) and 1 medium affinity (MA) (C); 2 LA and1MA (D); 5LA and 1MA (E); and 5LA, 1MA and 1HA (F). The combination of
continuous presence of LA and MA may be suggestive of continued formation of new, but leaky vessels.
doi:10.1371/journal.pone.0166655.g004
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However, to our knowledge, no model has yet described the process of normal wound healing
turning to pathological angiogenesis from the point of view of competition of angiogenesis
regulators for binding sites, a gap that we fill in this work.
In 1986, Dvorak suggested that tumors can be viewed as wounds that do not heal [1]. He
outlined the many similarities between normal wound healing process and tumor angiogene-
sis, and suggested that an understanding of normal vessel formation in wound healing would
enable interpretation of the abnormalities of blood vessel formation in tumor angiogenesis.
Wound healing/angiogenesis is a multistep process involving the uptake of angiogenesis regu-
lators by platelets, trapping of regulator-rich platelet clots in wounded tissues, and a well-
orchestrated secretion of positive and negative regulators of angiogenesis from the platelet
clots. As documented previously, platelet clots trap angiogenesis regulators [2], and release
them in response to tissue proteases [3]. The angiogenesis regulators are anchored in tissues to
surface glycosaminoglycans (GAGs) such as heparan sulfate (HS) [18], and their turnover is
facilitated by continuous secretion of heparinase and other tissue proteases by stromal ele-
ments. This sequence allows for sprouting, lumenization and regulation of blood vessels. The
early attachment of lowest affinity angiogenesis regulators such as VEGF (angiogenesis stimu-
lators) initiates sprout formation. Growth factors with medium affinity, such as PDGF-B and
bFGF (stabilizers) continue the process by stimulating endothelial cell proliferation, tube for-
mation, and vessel stabilization [13, 14, 30]. Cytokines with highest affinity (PF-4 and TSP-1)
are inhibitors that promote collagen cleavage and vessel pruning, effectively terminating the
wound healing process [7]. This is supported by the many fold excess of angiogenesis inhibi-
tors in platelets of normal human subjects [11], and explains the default postnatal “off” state of
postnatal angiogenesis.
It appears that vessel stabilization and pruning does not occur in tumors [31], resulting in a
continuous formation of immature, leaky blood vessels. We propose that this immature vessel
phenotype is a result of increased inflow of stimulators and stabilizers such as VEGF and
PDGF-B flooding the HS binding sites. Once the HS sites are occupied, inhibitors, such as PF-
4 or thrombospondin, which require more time in order to tightly bind, are prevented from
binding and terminating angiogenesis. To evaluate the implications of this hypothesis, we con-
structed an imitative agent-based model, which incorporates three types of growth factors
characterized by their ability to bind HS as low (VEGF), medium (PDGF-B) and high (PF-4)
affinity growth factors. The growth factors are motile and seek to bind to GAG on the surface
of cells they encounter, and vacate these binding sites as the activity of heparinase in the local
microenvironment increases. Despite setting only a minimal set of assumptions, we were able
to reproduce a pattern of behavior that corresponds to the expected behavior of angiogenesis
regulators during normal wound healing (see Fig 3). This theoretical model provides a very
plausible mechanistic explanation for the early part of a normal wound healing process, as well
as for pathological tumor angiogenesis.
A modification of the model, where an excess of low and medium affinity growth factors is
created (such as would be the case in malignant tumors), confirmed that such a cytokine
storm would preclude inhibitor binding and a successful inhibition of blood vessel formation.
The best way to envisage this type of interaction is as a game of musical chairs between growth
factors competing for binding sites. The theoretical model provides a novel framework for
understanding the sequential release and binding of angiogenesis regulators in wound healing
and tumor angiogenesis from the point of view of competitive inhibition. While both processes
commence the same way, the continuous inflow of stimulators and stabilizers that accompa-
nies early wound healing is not turned off in tumor invasion, because the advancing edge of
the growing tumor, does not allow time for tissue proteases to create pro-inhibitory microen-
vironment. Even though these angiogenesis regulators have distinctly separate receptors,
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anchoring to HS is a pre-requisite for effective signaling [19], and the binding at the glycan
level enables this competitive inhibition.
Model implications
We are working from our earlier findings that angiogenesis regulators are stored in
platelet alpha-granules, and released from platelet clots in response to tissue proteases. The
model, as presented here, does not provide information about the source, character or relative
proportions of the specific cytokines. An example of protease-facilitated growth factor release
from platelets is the thrombin Proteinase Activated Receptor (PAR) system. In this system
lower affinity growth factors are released in response to stimulation of PAR-1 (the high affinity
thrombin receptor stimulated even in low thrombin state), and higher affinity growth factors
are released upon stimulation of PAR-4 [3, 10].
There is a number of other local controls of growth factor release from platelet clots, such
as for example acidosis, oxygen tension and temperature [32–34]. The microenvironment of
tumors is known to have sites with low pH due to up-regulated glycolysis [35, 36], and
decreased pH leads to dramatic decrease of thrombin or collagen-induced secretion of vascular
Fig 5. Schematic representation of the proposed mechanism underlying normal wound healing, pathological angiogenesis and
differences in both dormant and progressive tumors.
doi:10.1371/journal.pone.0166655.g005
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endothelial growth factor [33]. Because pH is just one of the regulators of physiological func-
tions [37], the overall effect of release of inhibitors vs stimulators of angiogenesis is very het-
erogeneous even within a tumor microenvironment.
Within the context of normal wound healing, one can entertain the following: During
injury, loss of vascular integrity leads to deficient perfusion, increased rescue glycolysis, and
lowering of pH, providing a physiological signal for angiogenesis. Platelets, as early responders
to tissue injury deliver platelet-associated angiogenesis regulators (both stimulators and inhibi-
tors), and due to a relative absence of thrombin, heparinase or other tissue proteases, angio-
genesis stimulators are released first. The blood vessel damage and poor perfusion leads to
tissue ischemia and acidosis further de-activating PAR-4, and preventing release of angiogene-
sis inhibitors. This mechanism would allow for enhanced formation of new blood vessels until
pH is normalized, PAR-4 re-activated, inhibitors released, and angiogenesis switched off. The
hypoxia and low pH associated with tumor microenvironment effectively simulate this physio-
logical state of normal wound healing. The observation that low pH dramatically reduces
thrombin or collagen-induced secretion of vascular endothelial growth factor and endostatin
[33] may also provide a plausible explanation for the differences in cytokine profiles between
progressive and dormant tumors. Dormant tumors are small enough to avoid central necrosis,
and thus regions of increased acidosis, hyperthermia and hypoxia, and they retain a physiolog-
ical homeostasis with normal balance of predominance of angiogenesis inhibitors. These con-
siderations are summarized in Fig 5.
The agent-based model described in this manuscript provides a contextual framework for
understanding the differences between normal wound healing and unrestrained angiogenesis
in tumors. The mechanistic explanation provided by a competitive inhibition model may
allow experimental and therapeutic exploration that would give a competitive advantage to
angiogenesis inhibitors.
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